<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922023000300150</article-id>
<article-id pub-id-type="doi">10.22354/24223794.1139</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Factors associated with COVID-19 infection in People Living with HIV. A case-control study nested in a Colombian cohort]]></article-title>
<article-title xml:lang="es"><![CDATA[Factores asociados a la infección por COVID-19 en personas que viven con el VIH. Un estudio de casos y controles anidado en una cohorte colombiana.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alzate-Angel]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutierrez-Gomez]]></surname>
<given-names><![CDATA[Melissa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mueses-Marin]]></surname>
<given-names><![CDATA[Hector]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valderrama-Beltran]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A7"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sussmann-Peña]]></surname>
<given-names><![CDATA[Otto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A8"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martinez-Buitrago]]></surname>
<given-names><![CDATA[Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,REVIVA foundation  ]]></institution>
<addr-line><![CDATA[Valle del Cauca Cali]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,aff2  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Corporation for Biological Research  ]]></institution>
<addr-line><![CDATA[ Medellín]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,AIDS Fighting Corporation  ]]></institution>
<addr-line><![CDATA[Valle del Cauca Cali]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,San Ignacio University Hospital  ]]></institution>
<addr-line><![CDATA[Bogotá Cundinamarca]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Infectoclinicos  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,aff7  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af8">
<institution><![CDATA[,Scientific Assistance  ]]></institution>
<addr-line><![CDATA[Bogotá Cundinamarca]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Valle University  ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>27</volume>
<numero>3</numero>
<fpage>150</fpage>
<lpage>158</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922023000300150&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922023000300150&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922023000300150&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: People living with HIV (PLWH); can be especially vulnerable to the effects of SARS-Co V-2 and COVID-19. In this study, we evaluate the factors associated with acquiring COVID-19 and the severity of the infection among PLWH.  Materials and methods: Through a case-control study nested in a cohort, where cases were PLWH diagnosed with COVID-19; and controls were PLWH without the infection, 476 people were evaluated between May 1, 2020, and February 28, 2021. A univariate analysis was performed with the variables considered candidates. Binary logistic regression models were conducted for the COVID-19 outcome, and among those diagnosed with the infection, regression models for the outcome of hospitalization vs. outpatient treatment.  Results: Among 238 PLWH diagnosed with COVID-19, receiving integrase inhibitors p &lt; 0.001 (CI 95% 0.27,0.72) or protease inhibitors p 0.034 (CI 95%0.42,0.97) within their antiretroviral regime, was associated with a lower probability of developing COVID-19. 196 (82,35%) of the 238 cases received outpatient treatment, and 42 (17,64%) required hospitalization. In this case, being older than 50 years p 0.001 (CI 95% 1.8,9.64) and having obesity as a comorbidity p 0.017 (CI 95% 1.34,17.93) increased the possibility of requiring hospitalization, while receiving antiretroviral treatment or having received vaccination against influenza, decreased the likelihood of this outcome.  Conclusions: There are still many questions regarding whether there is a differential risk of acquiring COVID-19 among PLWH. Antiretroviral treatment with integrase or protease inhibitors; was associated with a lower probability of developing the co-infection. Some factors related to comorbidities, such as older age and obesity, draw attention to possible risk factors for hospitalization in this population. Discussing the feasibility of new studies with proposed causal hypotheses that allow directing the research designs toward a more precise answer to these questions is essential.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Las personas que viven con el VIH (PVV) pueden ser especialmente vulnerables a los efectos del SARS-CoV-2 y a la COVID-19. En el presente estudio, evaluamos los factores que se asocian a la presentación y severidad en esta población.  Materiales y métodos: A través de un estudio de casos y controles anidado en una cohorte, donde los casos fueron PVV, con diagnóstico de COVID-19 y los controles, PVV sin este diagnóstico, se evaluaron 476 personas entre el 1 de mayo de 2020 y el 28 de febrero de 202. Se realizó un análisis univariado y con las variables que se consideraron candidatas, se construyeron modelos de regresión logística binaria para el desenlace de COVID-19 y entre quienes presentaron esta infección, para el desenlace de hospitalización vs manejo ambulatorio.  Resultados: Entre 238 PVV diagnosticadas con COVID-19, el recibir tratamiento con inhibidores de integrasa p 0.001 (CI 95% 0.27,0.72) o inhibidores de proteasa p 0.034 (CI 95%0.42,0.97) fueron asociados con una menor posibilidad de presentar COVID-19. De los 238 casos, 196 (82,35%) fueron atendidos ambulatoriamente y 42 (17,64%) requirieron hospitalización. En este caso, la edad mayor de 50 años p 0.001 (CI 95% 1.8,9.64) y la obesidad p 0.017 (CI 95% 1.34,17.93) fueron factores que aumentaron la posibilidad de ser hospitalizado, mientras que el recibir tratamiento antirretroviral o haber recibido previamente vacunación contra influenza, disminuyeron la posibilidad de este desenlace.  Conclusiones: Aunque existen aún muchas preguntas acerca de si existe un riesgo diferencial de presentar COVID-19 en PVV y un riesgo aumentado de severidad en estas, algunos factores relacionados con la edad, tipo de antirretrovirales recibidos, vacunación previa con influenza y comorbilidades como la obesidad, llaman la atención sobre un posible rol como factores de riesgo aumentado o disminuido para estos desenlaces en esta población. Es importante discutir la factibilidad de realizar nuevos estudios con hipótesis causales planteadas que permitan dirigir los diseños de investigación hacia una respuesta más clara a estas preguntas.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[case and control studies]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[VIH]]></kwd>
<kwd lng="es"><![CDATA[estudios de casos y controles]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velavan]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The COVID-19 epidemic]]></article-title>
<source><![CDATA[Trop Med Int Heal]]></source>
<year>2020</year>
<volume>25</volume>
<page-range>278-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronavirus disease 2019: What we know?]]></article-title>
<source><![CDATA[J Med Virol]]></source>
<year>2020</year>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Antiga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronaviruses and immunosuppressed patients. The factsduring the third epidemic]]></article-title>
<source><![CDATA[Liver Transpl]]></source>
<year>2020</year>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spinelli]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[BLH]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Outcomes and Risk Factors Among People Living with HIV]]></article-title>
<source><![CDATA[Curr HIV/AIDS Rep]]></source>
<year>2022</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>425-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo (CAC). Situación del VIH SIDA en Colombia 2019]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Bogotá DC ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ernster]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nested case-control studies]]></article-title>
<source><![CDATA[Prev Med]]></source>
<year>1994</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>587-90</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peduzzi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Concato]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kemper]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Holford]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A simulation study of the number of events per variable in logistic regression analysis]]></article-title>
<source><![CDATA[J Clin Epidemiol]]></source>
<year>1996</year>
<volume>49</volume>
<page-range>1373-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbera]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Kamis]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Rowan]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV and COVID-19 review of clinical course and outcomes]]></article-title>
<source><![CDATA[HIV Res Clin Pract]]></source>
<year>2021</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>102-18</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Amo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Polo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy A Cohort Study]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
<volume>173</volume>
<page-range>536541</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dandachi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Montgomery]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Karmen-Tuohy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Golzy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Antar]]></surname>
<given-names><![CDATA[AAR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019]]></article-title>
<source><![CDATA[Clin Infect Dis an Off Publ Infect Dis Soc Am]]></source>
<year>2021</year>
<volume>73</volume>
<page-range>e1964-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbera]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Kamis]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Rowan]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shehata]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV and COVID-19 review of clinical course and outcomes]]></article-title>
<source><![CDATA[HIV Res Clin Pract]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>102-18</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abhinand]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnamurthy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oommen]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Sudhakaran]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential protease inhibitors and their combinations to block SARS-CoV-2]]></article-title>
<source><![CDATA[J Biomol Struct Dyn]]></source>
<year>2022</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>903-17</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<collab>RECOVERY Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY) a randomised, controlled, open-label, platform trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<numero>10259</numero>
<issue>10259</issue>
<page-range>1345-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
